{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:35Z","timestamp":1790294435334,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["NCT00949455"],"award-info":[{"award-number":["NCT00949455"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmoop.2026.108317","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:33:20Z","timestamp":1785900800000},"page":"108317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["HER1\u2013HER4 expression and co-expression in advanced urothelial carcinoma"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9769-5766","authenticated-orcid":false,"given":"S.","family":"Coca Membribes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Berney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0665-5210","authenticated-orcid":false,"given":"E.","family":"Nally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-4889","authenticated-orcid":false,"given":"F.","family":"Jackson-Spence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-0032","authenticated-orcid":false,"given":"B.","family":"Szabados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mariathasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7760-4724","authenticated-orcid":false,"given":"T.","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2026.108317_bib1","doi-asserted-by":"crossref","first-page":"9091","DOI":"10.1038\/s41598-021-88683-w","article-title":"The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers","volume":"11","author":"Majumder","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108317_bib2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41585-025-01075-x","article-title":"HER2 and urothelial carcinoma: current understanding and future directions","volume":"23","author":"Raggi","year":"2026","journal-title":"Nat Rev Urol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108317_bib3","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.bjc.6601245","article-title":"HER2\/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder","volume":"89","author":"Latif","year":"2003","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108317_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2-positive metastatic bladder cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108317_bib5","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"issue":"Suppl 7","key":"10.1016\/j.esmoop.2026.108317_bib6","article-title":"RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC","volume":"44","author":"Powles","year":"2026","journal-title":"J Clin Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.esmoop.2026.108317_bib7","volume":"44","author":"Powles","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108317_bib8","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","article-title":"Assessment of luminal and basal phenotypes in bladder cancer","volume":"10","author":"Guo","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108317_bib9","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108317_bib10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1464-410X.2005.05452.x","article-title":"Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases","volume":"95","author":"G\u00e5rdmark","year":"2005","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108317_bib11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/jso.21486","article-title":"Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy","volume":"101","author":"Yonemori","year":"2010","journal-title":"J Surg Oncol"},{"issue":"7492","key":"10.1016\/j.esmoop.2026.108317_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108317_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108317_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2026.108317_bib15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-025-08115-9","article-title":"HER3 promotes triple-negative breast cancer progression by upregulating PHF8 via miR-34b-5p-dependent mechanism","volume":"16","author":"Lyu","year":"2025","journal-title":"Cell Death Dis"},{"issue":"21","key":"10.1016\/j.esmoop.2026.108317_bib16","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/14796694.2025.2535280","article-title":"SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma","volume":"21","author":"Powles","year":"2025","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108317_bib17","first-page":"121","article-title":"Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer","volume":"3","author":"Lei","year":"2023","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108317_bib18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41467-025-67643-2","article-title":"Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer","volume":"17","author":"Chen","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108317_bib19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.annonc.2025.10.011","article-title":"Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial","volume":"37","author":"Powles","year":"2026","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:24:58Z","timestamp":1790292298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2059702926022593"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108317","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER1\u2013HER4 expression and co-expression in advanced urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108317"}}